Skip to main content
SpringerLink
Log in

Pregnancy outcomes following omalizumab exposure

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The Xolair Pregnancy Registry: An Observational Study of the Use and Safety of Xolair (Omalizumab) During Pregnancy; NCT00373061

Reference

  • Namazy JA, et al. Pregnancy Outcomes in the Omalizumab Pregnancy Registry and a Disease-matched Comparator Cohort Journal of Allergy and Clinical Immunology : 27 May 2019. Available from: URL: http://doi.org/10.1016/j.jaci.2019.05.019

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pregnancy outcomes following omalizumab exposure. Reactions Weekly 1757, 12 (2019). https://doi.org/10.1007/s40278-019-63240-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-63240-z

Search

Navigation